Abstract: A series of new 5-allyl-
Introduction
The reverse transcriptase (RT) of the human immunodeficiency virus type 1 (HIV-1 RT) is one of the main targets of drugs used in the treatment of AIDS [1, 2] . Several RT inhibitors have been developed and approved by the FDA and are currently in clinical use. Among several kinds of anti-HIV agents, non-nucleoside reverse transcriptase inhibitors (NNRTIs), specifically targeting to reverse transcriptase, have attracted wide attention due to their high specificity, excellent potency and low cytotoxicity [3, 4] . NNRTIs are a class of antiretroviral drugs which deactivate HIV-1 reverse transcriptase by inducing conformational change of the enzyme via binding to a hydrophobic site close (approximately 10 Å) to its catalytic site [5] . Since these compounds do not need intracellular metabolic activation, have relatively low cytotoxicity, act on a nanomolar scale and are not active against other retroviruses, they are highly specific HIV-1 inhibitors. Among NNRTIs, dihydro alkoxy benzyl oxopyrimdines (DABOs) are an interesting class of compounds active at nanomolar concentration. This class was first reported in 1992 and further developed during the following years into S-DABOs, N-DABOs and related analogues . Over the past decade, 2-alkylthio-6-benzylpyrimidin-4(3H)-ones (S-DABOs) have been the subject of great interest and have led to the identification of several new structures [27] [28] [29] displaying excellent activities as non-nucleoside inhibitors of HIV-1 reverse transcriptase (RT). In our continuing efforts to find novel effective and selective anti-HIV-1 agents in 2-alkylsulfanyl-6-benzyl-3,4-dihydropyrimidin-4(3H)-ones (S-DABOs) type NNRTIs [30] [31] [32] [33] , herein we present the synthesis and anti-HIV-1 activities of a series of S-DABO analogs.
Results and Discussion

Chemistry
The synthetic route of the newly designed compounds is described in Schemes 1 and 2. The key intermediate 5-allyl-6-benzyl-2,3-dihydro-2-thioxopyrimidin-4(1H)-one (1) was prepared through the method of our previously reported 3-step synthetic strategy [23] through the reaction of β-ketoester with thiourea in the presence of EtONa in refluxing EtOH. Subsequent S-alkylation of 1 with appropriate alkyl halides namely, methyl iodide, 1-bromoethanol, 1,3-dibrompropane, 1-bromohexane, allyl iodide, 1-bromo-2-(methoxymethoxy)ethane, bis(2-bromoethoxy)methane, methyl bromoacetate, ethyl bromoacetate, isobutyl bromide, 1-bromo-2-ethyl butane, cyclopentyl bromide, α-bromo-γ-butyrolactone, chloroethyl methyl ether and 3-bromo-1-prapanol in dry dimethylformamide (DMF) in the presence of anhydrous K2CO3 afforded the desirable target S-DABO analogues 2a-k. 5-Allyl-6-benzyl-2-(methyl acetatethio) pyrimidin-4(3H)-one 3a and 5-Allyl-6-benzyl-2-(ethyl acetatethio)pyrimidin-4(3H)-one 3b were obtained when compound 1 was treated with various halo-esters namely, methyl bromoacetate or ethyl bromoacetae in anhydrous DMF in the presence of K2CO3, respectively. The amide 4 was obtained upon treatment of 3a in 33% ethanolic methylamine. Also, the ester 3a was hydrolyzed to the corresponding acid 5 in hot aqueous potassium hydroxide (Scheme 1).
However, treatment of compound 1 with cyclohexyl bromide, afforded S-cycloalkyl derivative 6, which upon oxidation with m-chloroperbenzoic acid gave the corresponding cyclohexylsulfinyl derivative 7. Treatment of compound 6 with 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetan-2,4-disulfide (Lawesson's Reagent) in anhydrous benzene afforded 5-allyl-6-benzyl-2-(cyclohexylthio)pyrimidine-4(3H)-thione 8 (Scheme 2). 
Furthermore, reaction of 1 with 2-bromoacetaldehyde acetal in anhydrous DMF and K2CO3 at 65 °C gave the corresponding 5-allyl 6-benzyl-2-(2,2-diethoxyethylthio)pyrimidin-4(3H)-one 9 which was then treated with N,O-bis(trimethylsilyl) acetamide (BSA) using trimethylsilyl trifluoromethane-sulfonate (TMS triflate) as a catalyst to yield 5-(3,5-dimethylbenzyl)-6-allyl-3-ethoxy-2,3-dihydrothiazolo-[3,2-a]pyrimidin-7-one 10. Acyclic nucleoside Compounds 11a-c were obtained by S-alkylation of the key intermediate 2-thioxopyrimidin-4(1H)-one 1 with different acyclic halosugars (Scheme 2). All the target compounds were characterized by nuclear magnetic resonance (NMR), mass spectrum (MS) and elemental analysis. Both analytical and spectral data of all the newly prepared compounds are in full agreement with the proposed structures.
Pharmacological Screening
The anti-HIV activities and cytotoxicity's of the synthesized S-DABOs analogues are summarized in Table 1 . The expression of HIV-1 was quantified by two different methods, either the HIV-1 antigen detection assay enzyme-linked immunosorbent assay (ELISA) [34] or indirectly by the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay [35] . In general, the activity of the tested compounds including S-DABOs derivatives in the side chains at C-2 is to be expected when compared to those previously reported for S-DABOs. As illustrated in Table 1 , we could see that most of those compounds showed moderate to potent inhibition of RT activity, suggesting that HIV-1 RT was the target of this series of S-DABO derivatives. The activity and cytotoxicity of these newly synthesized S-DABO analogues were evaluated in MT-4 cells for their ability to inhibit HIV-1 in MT-4 cells,in comparison with (6-benzyl-1-(ethoxymethyl)-5-isopropylpyrimidine-2,4-dione (MKC-442) and azidothymidine (AZT) used as reference drugs. Most of the tested compounds exhibited moderate to good activities against wild-type HIV-1 with EC50 values ranged from 35.00 to 0.32 µM. The most active compound 11c showed the highest activity against wild-type HIV-1 with an EC50 value of 0.32 µM. The other compounds displayed moderate activity 2e, 2j, EC50 2.5 and 2.60 µM, respectively or were inactive 2c, 2k, 3b, 4 and 9, against HIV-1 replication. 
Experimental Section
Chemistry
All melting points were uncorrected and determined on a Büchi melting point apparatus (Hamburg, Germany). NMR spectra were recorded on a Varian Gemini 2000 NMR spectrometer (Varian Inc., Palo Alto, CA, USA) at 300 MHz for 1 
5-Allyl 6-(benzyl)-2-(methylthio)pyrimidin-4(3H)-one (2a).
A mixture of compound 1 (1.29 mmol), 10 mL hexamethyldisilazane (HMDS) and 10 mg (NH4)2SO4 were refluxed for 2 h. The remaining HMDS was removed under reduced pressure. 1 mL of anhydrous DMF and (2.24 mmol) of methyl iodide were added and the solution was stirred at room temperature for 5 h. 100 mL of dichloromethane was added and the solution was washed with 20 mL anhydrous NaHCO3. The organic layer was dried over Na2SO4 and evaporated till dryness under reduced pressure. The solid was washed with benzene to remove iodide and the solid was dissolved in CH2Cl2, dried and purified by column chromatography (30% EtOAc/pet.ether 60-80 °C) to give compound 2a in 94% yield, m.p. 
5-Allyl 6-(benzyl)-2-(alkylthio)pyrimidin-4(3H)-one (2b-k, 11b,c).
General procedure: To a stirred solution of compound 1 (3 mmol) in anhydrous DMF (10 mL) was added K2CO3 (3.3 mmol) and appropriate alkyl or cycloalkyl halides (3.3 mmol). The stirring was continued at room temperature for 8-12 h. The reaction mixture was poured into cold H2O (150 mL), the resulting precipitate was collected by filtration and washed sequentially with small portions of H2O, MeOH, Et2O and dried in vacuo to afford the corresponding crude product, which was purified by flash chromatography to give the pure target compounds. Allyl 6-benzyl-2-(cyclopentylthio)pyrimidin-4(3H)-one (2j) -4-benzyl-1,6-dihydro-6-oxopyrimidin-2-ylthio)-N-methylacetamide (4) . The ester 3a (0.60 mmol) was dissolved in 33% methylamine in EtOH (10 mL). When TLC showed no more starting material, the solution was evaporated in vacuo to dryness to give the amide derivative 4 in 100% yield, m.p. -4-benzyl-1,6-dihydro-6-oxopyrimidin-2-ylthio)acetic acid (5) . The ester 3a (0.9 mmol) was dissolved in hot (80 °C) aqueous potassium hydroxide (3 mL), and the solution was kept at this temperature for 5 min. After cooling, water was added (3 mL) and the pH adjusted to 7 with 4 M HCl. 
2-(2-Hydroxyethylthio)-5-allyl-6-benzylpyrimidin-4(3H)-one (2b
2-(3-Bromopropylthio)-5-allyl-6-benzylpyrimidin-4(3H)-one (2c
5-Allyl-6-benzyl-2-(2-((2-bromoethoxy)methoxy)ethylthio)pyrimidin-4(3H)-one (2g
5-Allyl-6-benzyl-2-(2-ethylbutylthio)pyrimidin-4(3H)-one (2i
5-
5-Allyl-6-benzyl-2-(tetrahydro-2-oxofuran-3-ylthio)pyrimidin-4(3H)-one (2k
5-Allyl-6-benzyl-2-(methylacetatethio)pyrimidin-4(3H)-one (3a
5-Allyl-6-benzyl-2-(ethylacetatethio)pyrimidin-4(3H)-one (3b
2-(5-Allyl
5-Allyl 6-benzyl-2-(cyclohexylthio)pyrimidin-4(3H)-one (6).
To a stirred solution of compound 1 (3 mmol) in anhydrous DMF (10 mL) was added K2CO3 (3.3 mmol) and cyclohexyl bromide (3.3 mmol). The stirring was continued at 80 °C for 6 h. The reaction mixture was poured into cold H2O (100 mL), the resulting precipitate was collected by filtration and dried in vacuo to afford the corresponding crude product, which was purified by flash chromatography (30% EtOAc/pet.ether 60-80 °C) to give compound 6 in 56% yield, m.p. 138-140 °C; 
6-Benzyl-2-(cyclohexylsulfinyl)-5-((oxiran-2-yl)methyl)pyrimidin-4(3H)-one (7).
A solution of compound 6 (2.5 mmol) and m-chloroperbenzoic acid (3 mmol) in dry dichloromethane (20 mL) was allowed to stand at room temperature for 48 h. The reaction mixture was diluted with chloroform (100 mL) and successively washed with 10% sodium bisulfite, 10% sodium thiosulfate, saturated sodium bicarbonate and water. After evaporation, the product was purified by preparative TLC (silica gel, CH2Cl2/MeOH 30:1) to give the title compound 7 in 37% yield, m.p. 
5-Allyl-6-benzyl-2-(cyclohexylthio)pyrimidine-4(3H)-thione (8).
A mixture of compound 6 (0.61 mmol) and 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetan-2,4-disulfide (Lawesson's Reagent) (0.92 mmol) in anhydrous benzene 50 mL was refluxed for 1 h. After cooling, the solvent was removed under reduced pressure and the precipitate formed was purified by passing through a silica gel column chromatography eluting with (20% CHCl3/pet.ether) to afford the title compound 8 in 53% yield, m.p. 
2-((Methylthio)methylthio)-5-allyl-6-benzylpyrimidin-4(3H)-one (11a).
A mixture of compound 1 (1.29 mmol), 10 mL HMDS and 10 mg (NH4)2SO4 were refluxed for 2 h. After evaporation under vacuum, the silylated compound was dissolved in 20 mL anhydrous MeCN and stirred at −40 °C. (4.0 mmol) of chloromethylmethyl sulfide was added, followed by dropwise addition of 0.40 mL TMS-triflate in 10 mL of anhydrous MeCN. The temperature was raised gradually to −15 °C and the mixture was kept at this temperature overnight, then the temperature was raised 5 °C per half hour. The reaction was stopped at 5 °C and 100 mL of CH2Cl2 was added. The mixture was washed with 20 mL saturated NaHCO3 and the organic layer was dried over Na2SO4 and evaporated till dryness under reduced pressure. The crude product was purified by flash chromatography (3% MeOH/CHCl3) to give the title product 11a in 74% yield, m.p. 218-220 °C; 1 Hydroxypropylthio)-5-allyl-6-benzylpyrimidin-4(3H)-one (11c) 
2-(3-
Pharmacological Screening
Virus and cells
The HIV-1 strains HTLV-IIIB and NNRTI resistant strain N 119 were propagated in H9 cells at 37 °C, 5% CO2 using RPMI 1640 with 10% heat-inactivated fetal calf serum (FCS) and antibiotics (growth medium). The culture supernatant was filtered (0.45 nm), liquated and stored at −80 °C until use. Both HIV-1 strains were obtained from the NIH AIDS Research and Reference program.
Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Replication
Compounds were examined for possible antiviral activity against both strains of HIV-1 using MT-4 cells as target cells. MT4 cells were incubated with virus (0.005 MOI) and growth medium containing the test dilutions of compounds for six days in parallel with virus-infected and uninfected control cultures without compound added. Expression of HIV in the cultures was quantitated by the HIV-1 antigen detection assay ELISA [27] or indirectly quantified using the MTT assay [28] . Compounds mediating less than 30% reduction of HIV expression were considered without biological activity. Compounds were tested in parallel for cytotoxic effect in uninfected MT-4 cultures containing the test dilutions of compound as described above. A 30% inhibition of cell growth relative to control cultures was considered significant. The 50% inhibitory concentrations (IC50) and the 50% cytotoxic concentrations (CC50) were determined by interpolation from the plots of percent inhibition vs. concentration of compound.
Conclusions
Non-nucleoside reverse transcriptase inhibitors (NNRTI) are key components in highly active antiretroviral therapy for treating HIV-1. Herein we present the synthesis for a series of S-DABOs analogues and evaluated as non-nucleoside HIV-1 reverse transcriptase inhibitors for inhibition of HIV-1 replication. Various chemical and spectral data supported the structures of the newly synthesized compounds. The majority of the tested compounds showed moderate to good activities against HIV-1 with an IC50 range from 35.60 to 0.32 µM. These results provided useful indicators for guiding the further rational design of new S-DABO analogues as more active and selective HIV-1 inhibitors.
